slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 44,491-44,520
Pages 2,019
Rows per page 30
Component
44,491-44,520 of 60,568
09
The slide uses a structured table to highlight gaps in current treatment standards.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
14
The slide uses a matrix-like structure to compare drug generations against clinical outcomes.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Loop · Mece Breakdown1 hit
16
Includes technical definitions of selectivity index and experimental conditions for Wistar Han rats.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
Includes detailed clinical trial enrollment metrics by dose cohort and patient population.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
19
Data cut-off: 8 Aug 2023. Includes detailed breakdown of resistance mutations and prior treatment history.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Data cut-off: 8 Aug 2023. N=93 patients.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The slide outlines a multi-cohort study design with specific patient populations and trial objectives.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
27
The slide uses a timeline-based framework to contrast current treatment options with clinical unmet needs.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
The slide presents a clinical trial snapshot including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
Includes a summary table of best responses and a waterfall plot showing percentage change in target lesions by dose cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Data as of 13 Sep 2022. N=35 patients.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
37
The slide outlines a multi-cohort study design for NVL-520, distinguishing between registrational cohorts and an exploratory cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
33
Includes a summary table of ORR and best response, and a waterfall plot showing individual patient tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
Data as of 13 Sep 2022. N=35 patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
38
The slide outlines a multi-cohort clinical trial design with specific patient segments based on prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
05
The slide uses a table-like structure to represent a clinical trial roadmap, incorporating regulatory designations and partner logos.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
09
Includes two line charts showing tumor volume reduction over time and a table showing patient incidence for target indications.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The slide uses a patient selection strategy based on ARID1a mutation status.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
21
The table segments indications by Squamous cell prevalence and NF2 mutation prevalence.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Voice Of Customer1 hit
22
Clinical trial identifier NCT05873686 is provided.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Traction1 hit
12
P3 Health Partners | Investor Conference Presentation Deck | 19 slidesP3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Loop · Hypothesis Test1 hit
18
The table includes adjustments for non-cash items like goodwill impairment and stock-based compensation.P3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations 1 hit
17
Includes a detailed income statement table and bulleted commentary on revenue and expense drivers.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
18
The table includes both absolute dollar values and key performance ratios like Net Interest Margin and Return on Average Assets.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · Market Size1 hit
29
Includes adjustments for gains/losses on asset disposals, rebranding, separation expenses, impairment, and tax effects.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · Team1 hit
30
The table provides a non-GAAP financial measure calculation for annualized NCOs/average loans and leases.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · Team1 hit
33
The table provides a granular view of lending segments including Structured Finance, Equipment Finance, Working Capital, Specialty Finance, Consumer Finance, Tax Services, and Corporate.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · Team1 hit